A syngeneic variance library for functional annotation of human variation:: Application to BRCA2

被引:65
作者
Hucl, Tomas [1 ]
Rago, Carlo [2 ,3 ]
Gallmeier, Eike [1 ]
Brody, Jonathan R. [1 ]
Gorospe, Myriam [4 ]
Kern, Scott E. [1 ]
机构
[1] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Howard Hughes Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Ludwig Ctr Canc Genet & Therapeut, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
[4] NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA
关键词
D O I
10.1158/0008-5472.CAN-07-6189
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The enormous scope of natural human genetic variation is now becoming defined. To accurately annotate these variants, and to identify those with clinical importance, is often difficult to assess through functional assays. We explored systematic annotation by using homologous recombination to modify a native gene in hemizygous (wt/Delta exon) human cancer cells, generating a novel syngeneic variance library (SyVaL). We created a SyVaL of BRCA2 variants: nondeleterious, proposed deleterious, deleterious, and of uncertain significance. We found that the null states BRCA2(Delta ex11/Delta ex11) and BRCA2(Delta ex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Delta ex11/Y3308Y), BRCA2(Delta ex11/P3292L) ,and BRCA2(Delta ex11/P3280H) had wild-type function. A proposed phosphorylation site at codon 3291 affecting function was confirmed by substitution of an acidic residue (glutamate, BRCA2(Delta ex11/S3291E)) for the native serine, but in contrast to a prior report, phosphorylation was dispensable (alanine, BRCA2(Delta ex11/S3291A)) for BRCA2-governed cellular phenotypes. These results show that SyVaLs offer a means to comprehensively annotate gene function, facilitating numerical and unambiguous readouts. SyVaLs may be especially useful for genes in which functional assays using exogenous expression are toxic or otherwise unreliable. They also offer a stable, distributable cellular resource for further research.
引用
收藏
页码:5023 / 5030
页数:8
相关论文
共 38 条
[1]   Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells [J].
Abbott, DW ;
Freeman, ML ;
Holt, JT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (13) :978-985
[2]  
AUERBACH AD, 1993, EXP HEMATOL, V21, P731
[3]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[4]   Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation [J].
Connor, F ;
Bertwistle, D ;
Mee, PJ ;
Ross, GM ;
Swift, S ;
Grigorieva, E ;
Tybulewicz, VLJ ;
Ashworth, A .
NATURE GENETICS, 1997, 17 (04) :423-430
[5]   Role of BRCA2 in control of the RAD51 recombination and DNA repair protein [J].
Davies, AA ;
Masson, JY ;
Mcllwraith, MJ ;
Stasiak, AZ ;
Stasiak, A ;
Venkitaraman, AR ;
West, SC .
MOLECULAR CELL, 2001, 7 (02) :273-282
[6]   CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair [J].
Esashi, F ;
Christ, N ;
Gannon, J ;
Liu, YL ;
Hunt, T ;
Jasin, M ;
West, SC .
NATURE, 2005, 434 (7033) :598-604
[7]   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921
[8]   Thymic model for examining BRCA2 expression and function [J].
Flores, KG ;
McAllister, KA ;
Greer, PK ;
Wiseman, RW ;
Hale, LP .
MOLECULAR CARCINOGENESIS, 2002, 35 (03) :103-109
[9]   Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2:: Analysis of 10,000 individuals [J].
Frank, TS ;
Deffenbaugh, AM ;
Reid, JE ;
Hulick, M ;
Ward, BE ;
Lingenfelter, B ;
Gumpper, KL ;
Scholl, T ;
Tavtigian, SV ;
Pruss, DR ;
Critchfield, GC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1480-1490
[10]   Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX [J].
Gallmeier, E ;
Winter, JM ;
Cunningham, SC ;
Kahn, SR ;
Kern, SE .
CARCINOGENESIS, 2005, 26 (10) :1811-1820